--TransCode Therapeutics, Inc., a clinical-stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, released its poster 1025 P describing the clinical results from its Phase 1 a clinical trial of TTX-MC138 at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
--TransCode Therapeutics, Inc., a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced updated clinical data from its Phase 1 a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic candidate, in patients with relapsed or refractory, unresectable...
Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar today, September 16, 2026, at 4:15 p. ET with TransCode Therapeutics, Inc.
Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 3, 2026 / RedChip Companies will host an investor webinar on Wednesday, September 16, 2026, at 4:15 p. ET with TransCode Therapeutics, Inc.
This is the newest page. Registered accounts read further back.